Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer

EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing - Vivani Medical (NASDAQ:VANI)

Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management.

Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer

The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes.

Medical Breakthroughs In Weight Loss: ESG, Gastric Balloons, And The New Era Of Treatment

The fight against obesity has taken a significant turn in recent years, with medical advancements providing new hope for individuals seeking effective weight-loss solutions.  Among these breakthroughs are Endoscopic Sleeve Gastroplasty (ESG) and intragastric balloons, both of which offer innovative approaches to weight management without the need for invasive surgery. This article explores these cutting-edge ... The post Medical Breakthroughs In…

You haven’t gotten used to the names Ozempic and Wegovy yet, and now you’ll have to learn some new ones: CagriSema, UBT251, Retatrutide. Today they sound like random codes, but they are the next frontier in the fight against obesity and diabetes, diseases that continue to claim victims throughout the Western world. Semaglutide-based weight-loss drugs are still radically transforming the approach to weight loss, with results that until a few year…

Eli Lilly's Obesity Pill Data Release Could Shake Up the Weight Loss Drug Market

Eli Lilly's orforglipron, a once-daily pill, could transform the weight loss drug market with its needle-free convenience and potential market dominance.

Eli Lilly Launches Mounjaro® in India

Adults taking Mounjaro® with diet and exercise in a controlled clinical trial lost on average 21.8 kg. at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg) over a period of 72 weeks. Individual results may varyMounjaro® delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trialsMounjaro®, a once-weekly injection is a prescription medicine and should be used under medical adviceEli Lilly and Company (Ind…